Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
Diagnosis and evaluation of multiple myeloma is a critical first step in delivering personalized, life‑extending treatment. At Liv Hospital, our international patient program ensures that every step—from laboratory testing to advanced imaging—is coordinated with the comfort and convenience of patients traveling from abroad. Each year, over 30,000 new cases of multiple myeloma are identified worldwide, and early, accurate assessment dramatically improves outcomes. This page explains the comprehensive diagnostic pathway we follow, the specialized tests involved, and how our multidisciplinary team interprets the results to create an optimal care plan.
Whether you are a newly referred patient, a caregiver seeking clarity, or a physician looking for a detailed overview of our evaluation protocol, the information below outlines the full spectrum of assessments performed at Liv Hospital. By understanding each component of the process, you can feel confident that the diagnosis and evaluation you receive meet the highest international standards, supported by JCI accreditation and cutting‑edge technology.
Multiple myeloma is a malignant disorder of plasma cells that accumulate in the bone marrow, disrupting normal blood formation and producing abnormal proteins. The disease often presents with bone pain, anemia, hypercalcemia, and renal impairment, but symptoms can be subtle and overlap with other conditions, underscoring the need for thorough assessment.
Because these manifestations vary widely, a systematic diagnosis and evaluation process is essential to differentiate multiple myeloma from other hematologic or skeletal disorders.
Accurate staging guides treatment intensity, and each component of the evaluation contributes to assigning the correct stage.
The first phase of diagnosis and evaluation involves a series of blood and urine examinations that reveal the biochemical footprint of multiple myeloma. These tests are performed in our accredited laboratory, ensuring rapid turnaround and precise quantification.
These laboratory studies form the backbone of the diagnostic algorithm, allowing clinicians to confirm the presence of a clonal plasma‑cell population and assess disease burden.
Imaging complements laboratory data by revealing skeletal lesions, soft‑tissue masses, and organ infiltration. At Liv Hospital, we employ a tiered imaging strategy tailored to each patient’s clinical presentation.
Integrating imaging findings with laboratory results completes the diagnosis and evaluation process, enabling precise disease mapping.
A definitive diagnosis requires direct visualization of plasma cells within the marrow. Our hematology team performs a minimally invasive bone‑marrow aspiration and trephine biopsy under local anesthesia, ensuring patient comfort and high‑quality specimens.
The combination of morphologic and genetic data refines risk stratification and informs the selection of targeted agents, such as proteasome inhibitors or monoclonal antibodies.
Beyond the International Staging System (ISS), modern diagnosis and evaluation incorporates cytogenetic risk and patient‑specific factors to produce a comprehensive prognostic profile.
The R‑ISS combines ISS, cytogenetics, and serum lactate dehydrogenase (LDH) levels, offering a more nuanced prediction of overall survival.
These scores guide therapeutic intensity, eligibility for clinical trials, and counseling of patients and families.
Effective diagnosis and evaluation is not limited to laboratory and imaging results; it requires the coordinated expertise of a dedicated team. Liv Hospital’s international patient program brings together hematologists, radiologists, pathologists, transplant specialists, and supportive‑care professionals under one roof.
By uniting all aspects of the diagnostic journey, we reduce delays, enhance accuracy, and ensure that every patient receives a treatment plan that reflects the full depth of their evaluation.
Liv Hospital combines JCI accreditation, state‑of‑the‑art technology, and a dedicated international patient program to deliver world‑class multiple myeloma care. Our multidisciplinary team tailors each step of the diagnosis and evaluation process, while our concierge services handle travel, accommodation, and language needs, allowing patients to focus on health and recovery.
Ready to begin your personalized diagnostic journey? Contact Liv Hospital today to schedule a virtual consultation and let our experts guide you through every step of the evaluation process.
Send us all your questions or requests, and our expert team will assist you.
Initial laboratory evaluation begins with a complete blood count to assess anemia and platelet levels, followed by serum protein electrophoresis (SPEP) to detect monoclonal (M) protein. Immunofixation characterises the M‑protein type, while the serum free light‑chain assay quantifies κ and λ light chains, identifying non‑secretory disease. β2‑microglobulin provides prognostic information for ISS staging, and calcium and renal function panels evaluate organ involvement (CRAB criteria). Urine studies, including a 24‑hour urine protein electrophoresis and urine immunofixation, detect Bence Jones proteins, confirming light‑chain disease. Together these tests confirm a clonal plasma‑cell disorder and gauge disease burden.
Imaging is essential for detecting lytic bone lesions, fractures, and extramedullary disease. A conventional skeletal survey provides a baseline overview of lytic lesions at low cost. Advanced modalities such as MRI offer high‑resolution assessment of bone‑marrow infiltration and spinal cord compression, while CT evaluates cortical bone integrity. PET/CT adds functional information by highlighting metabolically active lesions and monitoring treatment response. The combination of these studies with laboratory results completes the staging process, informing treatment intensity and prognosis.
The International Staging System (ISS) classifies myeloma into three stages based solely on serum β2‑microglobulin and albumin, providing a simple risk estimate. The Revised ISS (R‑ISS) incorporates the same laboratory values but also includes high‑risk cytogenetic abnormalities (del 17p, t(4;14), t(14;16)) and serum lactate dehydrogenase (LDH) levels. By integrating genetic and metabolic data, R‑ISS offers a more nuanced prediction of overall survival and better guides therapeutic decisions, especially for patients considered high‑risk by cytogenetics.
A bone‑marrow aspiration and trephine biopsy enable pathologists to assess the percentage of clonal plasma cells, which must be ≥10 % for a definitive diagnosis. Flow cytometry characterises immunophenotypic markers (CD38, CD138, CD56), while fluorescence in situ hybridisation (FISH) detects high‑risk cytogenetic lesions such as del 17p, t(4;14), and t(14;16). Next‑generation sequencing can uncover emerging molecular markers. These combined morphologic and genetic data refine risk stratification, influence treatment selection (e.g., proteasome inhibitors, monoclonal antibodies), and are required for staging under both ISS and R‑ISS.
The hospital’s International Patient Program assigns a dedicated coordinator who assists with travel logistics, visa support, and accommodation. All diagnostic procedures are performed in JCI‑accredited laboratories and imaging suites, ensuring high quality and rapid turnaround. Multilingual staff translate reports and treatment plans into the patient’s preferred language. A multidisciplinary tumor board reviews each case, and the final personalized care plan is presented in a culturally sensitive manner, with continuous follow‑up throughout therapy.
BlogHematologyApr 08, 2026Did you know that blood disorders affect millions of people worldwide, causing a wide range of health issue...
BlogHematologyApr 07, 2026Every year, over 1.8 million people in the United States get cancer. Hematology oncology is key in fighting...
BlogHematologyApr 06, 2026Pulmonary hemorrhage is a serious condition where blood enters the lung tissue and airways suddenly or over...
BlogHematologyApr 03, 2026Vitamin B12 and folic acid are key nutrients. They help keep red blood cells healthy, support nerve functio...
BlogHematologyApr 03, 2026Vitamin B is key for our health, helping with energy and brain function. At LivHospital, we know how import...
BlogHematologyApr 03, 2026Vitamin B12 and folate (vitamin B9) are essential nutrients for our nerves and for making red blood cells. ...
